{Reference Type}: Journal Article
{Title}: Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.
{Author}: Okamoto A;Glasspool RM;Mabuchi S;Matsumura N;Nomura H;Itamochi H;Takano M;Takano T;Susumu N;Aoki D;Konishi I;Covens A;Ledermann J;Mezzanzanica D;Mezzazanica D;Steer C;Millan D;McNeish IA;Pfisterer J;Kang S;Gladieff L;Bryce J;Oza A;
{Journal}: Int J Gynecol Cancer
{Volume}: 24
{Issue}: 9
{Year}: Nov 2014
{Factor}: 4.661
{DOI}: 10.1097/IGC.0000000000000289
{Abstract}: Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than high-grade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.